The objective of this case-control study, conducted in a large Italian university hospital over a 12-month period, was to evaluate the risk factors associated with the emergence of azole resistant oral candidosis in 64 Human Immunodeficiency Virus (HIV) infected patients. A swab was obtained from each patient by brushing candidal lesions. Candida albicans was isolated in 41 patients (64%), Candida glabrata in ten (16%), Candida krusei in five (8%), Candida kefyr in two (3%), Candida tropicalis in two (3%), and Candida lipolytica and Candida guilliermondii in one case, respectively. Two patients suffered a double infection i.e. C. albicans + C. krusei and C. albicans + C. glabrata, respectively. Candida species were tested in vitro for their susceptibility to ketoconazole, fluconazole, itraconazole and amphotericin B. MICs of the four antifungal drugs were obtained for each yeast using a microdilution broth method developed in our laboratory. Twenty four (37%) of the isolated strains were resistant both to itraconazole and fluconazole, five (8%) to fluconazole alone, and two (3%) to ketoconazole alone, while none of the isolated strains was resistant to amphotericin B. Patients with oral candidosis caused by a strain resistant to one or more azole drug were compared to control patients with azole-susceptible oral candidosis. On univariate analysis, more than five episodes of oral candidosis in the last year (P = 0.01), previous use of azole therapy (P = 0.001), C2-3 category of HIV infection (P = 0.01) and low number of circulating CD4+ T-cells (P = 0.03) were significantly associated with an increased risk for the development of azole resistance. However, previous use of azole therapy was the only factor selected by a stepwise logistic regression analysis which was independently associated with the isolation of azole resistant strains (P = 0.003). Our findings indicate that, in view of the potential risk for the emergence and selection of azole resistant strains of Candida in patients with AIDS, it is important to carefully choose the antifungal drug for the therapy of mild fungal infections after evaluation of the in-vitro susceptibility of the isolated strains.
Introduction
Candida spp. are the commonest causative agents of fungal infections in Human, Immunodeficiency Virus (HIV) infected patients (Feigal et al,, 1991; Polis & Kovacs, 1992) . These infections are seldom invasive as indicated by the frequent observation of oropharyngeal candidosis and oesophagitis in patients with AIDS and AIDS-related, conditions, and the rare occurrence of candidal pneumonia or septicaemia in the same group of patients (Whimbey et al., 1986; Spencer & Jackson, 1989) . Oral candidosis is an indirect marker of the impairment of the immune system and a prognostic indicator, in individual patients, for the subsequent development of AIDS (Rothenberg et al., 1987) .
Treatment of oral candidosis is straightforward and a variety of agents are presently available (Grant & Clissold, 1989; Meunier, Aoun & Gerard, 1990; Rogers et al., 1992; Sargeorzan et al., 1994) . Topical therapy (e.g. nystatin) is often the initial treatment of choice because of its easy administration and relatively low cost, although it is usually unable to control oral caudidosis for long. Therefore oral azoles (i.e. ketoconazole and more recently fluconazole and itraconazole) are the drugs more extensively used in the therapy of oral candidosis in HIV infected patients (Grant et al., 1989; Meunier et al., 1990) . Despite their pharmacological and clinical effectiveness, persistent and/or recurrent episodes of oral candidosis are often observed in HIV infected patients (Sargeorzan et al., 1994) and oral candidosis not responsive to fluconazole, has been reported both in HIV infected and in other immunocompromised patients (Boken, Swindells & Rinaldi, 1993; Ng & Denning, 1993; Baily et al., 1994; Redding et al., 1994; Rex, Rinaldi & Pfaller, 1995) . This is the consequence of the emergence of fluconazole resistant strains of Candida, especially Candida glabrata and Candida krusei.
The objective of this study was to identify the frequency of azole resistant Candida spp. in HIV infected patients with oral candidosis and in particular, the pattern of susceptibility of the isolated strains to fluconazole, itraconazole and ketoconazole. We have also evaluated, through a statistical analysis, the risk factors associated with the emergence of azole resistant Candida spp.
Methods

Patients
The study population consisted of 100 patients, randomly selected from 986 HIV infected patients observed in a large Italian university hospital with HIV in-and out-patient units, over a 12-month period (1 June 1994 -31 May 1995 . All HIV infected patients selected in the study period were clinically examined with particular attention to the oropharynx. A typical appearance was considered sufficient for the diagnosis of oropharyngeal candidosis. We distinguished three types of oral candidosis: a pseudomembranous form with removable creamy, whitish, curdlike plaques involving buccal mucosa, tongue and other oral mucosal surfaces; an erythematous form with smooth red patches on the hard or soft palate, dorsal surface of the tongue and buccal mucosa; and a hyperplastic form with whitish, barely palpable patches or firmly adherent rough plaques most commonly affecting the buccal mucosa bilaterally. Patients with concurrent Candida infections elsewhere were not included in the study. The follow up of the patients with oral candidosis ended 30 September 1995, with a mean follow up time of 4 ± 2 months.
To identify the risk factors associated with the development of azole resistant Candida infections, we performed a case-control study considering all patients with oral candidosis selected in the study period. The cases had an isolate of Candida spp., resistant to at least one azole drug (fluconazole, itraconazole or ketoconazole) from an oral swab while the controls were those with isolates susceptible to all three above mentioned drugs.
The following data were routinely obtained in all patients included in the study: age, sex, HIV risk behavior, stage of HIV infection, AIDS-related diseases, antiretroviral therapy and prophylaxis for opportunistic infections. In addition, other factors potentially correlated with the development of Candida spp. infections and/or with the emergence of resistance to azole drugs were investigated: number (x mm 3 ) of circulating CD4+ T cells and polymorphonuclear (PMN) cells, use of steroids, antineoplastic chemotherapy, broad spectrum antibiotic or antifungal therapy or prophylaxis in the previous six months, use of drugs well known to interact with azoles (rifamycins, cimetidine, oral contraceptives, phenytoin and carbamazepine) and total number of episodes of oral candidosis in the year preceding the study.
Mycological investigations
A swab was taken from each patient with oral candidosis by brushing candidal lesions. The swabs were immediately inoculated onto Bacto Candida Growth (BCG) agar plates (Difco Laboratories, Detroit, MI, USA) and Sabouraud dextrose with chloramphenicol (50 mg/L) (SabC) agar slants. The plates were incubated at 37°C and the slants at 25°C. Samples were also examined microscopically by Gram's stain. A single colony of each macroscopically different yeast was subcultured on SabC plates for 24 h at 37°C for identification and susceptibility testing. Identification was carried out using germ tube test in bovine fetal serum and a Yeast Biochemical Card of the Automicrobic Vitek System (Bio Merieux, Rome, Italy). In individual cases, identification was confirmed through observation of morphological characteristics. The same subculture was used for preparing the suspension for susceptibility testing of each species.
Antifungal agents
Four antifungal drugs were supplied as powders by their manufacturers: ketoconazole and itraconazole (Janssen, Italy S.p.a.) fluconazole (Pfizer Italy S.p.a.) and amphotericin B (BristolMeyers Squibb).
Media
Several media were used for in-vitro antifungal susceptibility testing: Antibiotic Medium 3 (Difco) for amphotericin B and ketoconazole; Brain Heart Infusion (BBL) for itraconazole; and High Resolution (Pfizer Central Research, Sandwich, Kent, UK) buffered with MOPS (pH 7.5) for fluconazole.
Susceptibility testing
The assay was performed using a microdilution broth method developed in our laboratory and reported elsewhere in more detail (Polonelli & Morace, 1984; Morace, Manzara & Dettori, 1991; Morace el al., 1995) . Stock solution of the four antifungal agents were prepared in distilled water (fluconazole), dimethylsulphoxide (amphotericin B and ketoconazole), or alcohol (itraconazole). Stock solutions were then diluted in the chosen medium (see above) performing a two-fold dilution in order to obtain final drug concentrations of 0.004-10 mg/L for amphotericin B and of 0.04-100 mg/L of medium for all other agents. Predetermined quantities (0.1 mL) of the different media with the expected antifungal drug concentrations were automatically dispensed into 96 micro-well plates using a Dynatech 2000 dispenser. Media with or without the solvents used for preparation of antifungal stock solutions were also dispensed for controlling the growth of the yeasts tested. Micro-well plates were frozen at -20°C before use. They remain stable for 1 year (Polonelli & Morace, 1984) . Inocula of the yeast isolates were prepared in sterile distilled water from the culture grown for 24 h at 25°C on Modified Sabouraud glucose agar (BBL). The suspensions were adjusted to give a concentration of 10* cells/mL, determined by spectrophotometric reading at 650 nm. The suspensions were then diluted 1:10 in sterile distilled water to obtain a total volume of 40 mL. 1.5 ^L were automatically dispensed into each well of the microtiter plate using a Dynatech 2000 inoculator. The plate was sealed to prevent evaporation and incubated at 30°C. After 48 h of incubation, the plates were read and the lowest concentration of the drugs without visible growth of the yeast was recorded as the MIC. Although there are no defined breakpoints for antifungal agents, isolates were considered susceptible to the antifungal agents when the MIC was 8 mg/L for ketoconazole and fluconazole, and 1 mg/L for amphotericin B and itraconazole (Espinel-Ingroff & Pfaller, 1995) .
Statistical analysis
Difference in means were tested for normal distribution and compared using Student's two tailed /-test. Differences in group proportions were assessed using % 2 test or > f°r small numbers, using Fisher's exact test. Potential risk fators for azole resistance were analyzed by univariate methods to screen for possible inclusion into a multivariate models. Test-based confidence intervals (CI) were used to determinate the statistical significance of the relative risk (RR). Multivariate analysis was performed with logistic regression models and 95% CI were used to determinate the statistical significance of the relative risk (mRR). Statistical analyses were performed with a software program Egret (Statistics and Epidemiology Research Corporation, Seattle, WA, USA).
Results
We observed 64 patients with oral candidiasis out of the 100 HIV infected patients selected for the study. Forty-seven patients (73%) were males and 17 (27%) females with a mean age of 33.1 ±5 years (range 21-45). Forty-six patients (72%) were intravenous drug abusers, 12/64 (19%) were homosexual. According to the CDC AIDS classification (CDC, 1992) , eight patients (13%) were categories B2 and B3 and 56 (87%) in categories C2 and C3. The mean number of circulating PMN and CD4+ T-cells was 2820 ± 1229/mm 3 (range 549-8790) and 110±54/mm 3 (range 2-349), respectively. Candida albicans was isolated in 41/64 patients (64%), C. glabrata in 10/64 (16%), C. krusei in five/64 (8%), Candida kefyr'm two/64 (3%), Candida tropicalis in two (3%), and Candida lipolytica and Candida guilliermondii in one case, respectively. Two patients suffered a double infection i.e. C. albicans + C. krusei and C. albicans + C. glabrata, respectively. Fifty-two patients (81%) suffered at least one episode of oral candidosis in the previous year with a mean of 3 ± 2 (range 1-11) episodes. Forty-three patients (67%) received azole treatment in the six months prior to inclusion in the study. Thirty-five patients (54%) were treated with fluconazole, 11 (17%) with itraconazole and three (5%) with ketoconazole. None of the patients had received antifungal prophylaxis except for two patients with non-Hodgkin's lymphoma, who had been given antifungal prophylaxis with fluconazole (100 mg/po/daily) during chemotherapy.
Twenty four (37%) of the isolated strains were resistant to both itraconazole and fluconazole, five (8%) to fluconazole alone, and two (3%) to ketoconazole, while none of the strains was resistant to amphotericin B.
Clinical findings and treatment
Forty-eight patients (75%) suffered pseudomembranous, ten (16%) erythematous and six (9%) hyperplastic forms of oral candidosis. There was no statistically significant difference regarding the isolation of azole resistant strains of Candida spp. from the various forms. At the time of the diagnosis of oral candidosis, 44 patients (69%) were empirically treated with oral fluconazole (100 mg daily), 16 (25%) with oral itraconazole (100 mg daily) and four (12%) with ketoconazole (200 mg daily). Thirty-five patients (55%) improved clinically but some required an increased dosage of the drugs (up to 400 mg daily). The remaining 29 patients with persistent oral candidosis were treated according to the in-vitro susceptibility of the isolates, with ketoconazole (200-400 mg daily; 14 patients), itraconazole (100-200 mg daily; four patients) and iv amphotericin B (0.3-0.5/mg/kg, daily; 11 patients) with a complete clinical remission in 90%. Three patients (treated with ketoconazole up to 400 mg daily) had only a partial remission and received iv amphotericin B (0.3 mg/kg daily) with a complete resolution of oral candidosis.
Twenty-nine-patients (19 cases and ten controls) had one or more relapses a median of 24 days (range 7-152 days) following the treatment. In eight patients new species of Candida were isolated and 50% of these were azole resistant. Twenty-one patients had recurrences due to the same species of Candida as previously isolated; one of them had become fluconazole resistant and two ketoconazole resistant, while the remaining patients had the same pattern of in-vitro susceptibility observed in the previous episode of oral candidosis.
Case-control study
Thirty-one patients (48%) with oral candidosis had an infection resistant to at least one azole drug. These were the cases while the other 33 patients with azole susceptible oral candidosis acted as controls. The differences between cases and controls are summarized in Table I . Using univariate analysis, the following factors were significantly associated with the development of azole resistant Candida spp.: (1) more than five episodes of oral candidosis in the previous year (P = 0.0001); (2) azole therapy in the previous six months (P = 0.001); (3) C2-3 categories of HIV infection (P = 0.01; and (4) <50/mm 3 circulating CD4+ T-cells (P = 0.03). The following factors were not significantly associated with the development of resistant Candida spp.: HIV risk behavior, AIDS-related diseases, antiretroviral therapy, prophylaxis of AIDS-related diseases, antineoplastic chemotherapy, use of steroids and broad spectrum antibiotic therapy.
Cases were approximately twice as likely to have received an antifungal drug in the six months preceding inclusion in the study. Fluconazole had been prescribed in 22 cases and nine controls (P = 0.001), itraconazole in nine cases and two controls (P = 0.03) and ketoconazole in two cases and one control (P = ns) (see Table I ). No statistical significant difference was observed regarding the species of Candida isolated in cases and controls (see Table II ). However, previous treatment with fluconazole was significantly associated with the development of oral infection with azole resistant Candida other than C. albicans (P = 0.008) (see Table III ).
After multivariate analysis, previous therapy with an azole drug was the only risk Table HI . Azole therapy in the previous six months and isolation of C. albicans and non-albicans strains of Candida in cases and controls
Candida spp.
C. albicans non-C. albicans
•(9 vs 14) P = 0.008. factor that independently influenced the isolation of resistant Candida spp. {P = 0.003, mRR = 8.97, 95% CI = 1.21-45.36).
Discussion
Oropharyngeal candidosis, although not a life-threatening disease, is often the first opportunistic manifestation of HIV infection and more than two thirds of patients with AIDS present with episodes of oral thrush (Sargeonzan et ah, 1994) . The relative ease of treating oral candidosis contrasts with the high rate of recurrences (more than 50% within 1 month after successful treatment) (Spencer et al., 1989) . In addition, a few patients with HIV infection suffer persistent oral candidosis and, in them, repeated courses of antifungal therapy only produce clinical improvement without eradication of the Candida (Baily et al., 1994; Barchiesi et al., 1995) . However, while the clinical evaluation of oral candidosis is an indirect assessment of drug efficacy, the use of quantitative oral cultures provides an additional means of directly evaluating the effect of antifungal therapy, in particular in patients with persistent oral candidosis (Epstein, Pearsall & Truelove, 1980) . Ketoconazole was the first oral drug extensively used for the treatment of candidosis in patients with AIDS and since the 1980's ketoconazole resistant isolates of Candida spp. have been increasingly described in HIV infected patients (Hughes et al., 1988) . In the beginning of the 1990's the first cases of fluconazole resistant candidosis were observed (Diz et al., 1993) and a marked increase in the incidence of clinical failure of fluconazole therapy for oral candidiasis has been subsequently reported (Boken et al., 1993; Ng et al., 1993) . It is possible to speculate that the extensive and long-term use of fluconazole could have determined the selection of C. albicans phenotypes with a reduced susceptibility to fluconazole and/or the emergence of non-albicans strains which are less susceptible to azole drugs (Redding et al., 1994; Wood, 1994) .
Our study confirms the increasing problem of azole resistance in the course of HIV infection, since about half of our patients with oral candidosis had a strain isolated which was resistant in vitro to at least one azole drug. Although the higher rate (45%) of resistance was to fluconazole, a significant proportion (38%) of Candida isolates were also resistant to itraconazole. In our opinion, this is probably due to both a cross resistance with fluconazole and increasing use of itraconazole in HIV infected patients. On the other hand, an interesting finding of our study is the generally good susceptibility of the isolates of Candida spp. to ketoconazole (only 3% of strains were resistant in vitro) suggesting that azole cross resistance is not inevitable. Since all azole drug have a similar basic mechanism of action (Bennett, 1990) , it may be that different mechanisms of azole resistance may be responsible for azole cross resistance or fluconazole resistance only. The low resistance to ketoconazole observed in our study could be due to the reduced use of this drug over the last decade and the consequent selection of fluconazole-itraconazole resistant and ketoconazole susceptible strains. Furthermore, a change in the biochemical and physical proprieties of cell membranes has a greater effect on the uptake of fluconazole than of ketoconazole which is an hydrophobic drug, and this difference may further explain the absence of cross resistance between fluconazole and ketoconazole.
Hitherto there have been few reports of an association between previous therapy with fluconazole, a low CD4+ cell count, intravenous drug abuse and the development of fluconazole resistant oral candidiasis in HIV infected patients (Chavanet et al., 1994; Dios et al., 1995) . Our analysis showed that oral infections with azole resistant Candida spp. occur more frequently among patients with certain identifiable risk factors: previous azole therapy; advanced stage of HIV infection; and a high number of episodes or oral candidosis in the previous year. Many of these factors appears inter-related. One hypothesis is that in advanced HIV infection there is a lack of response to azole therapy as a result of both profound T lymphocyte dysfunction and also dysfunction of other host defenses against Candida, such as neutrophil and monocyte fungicidal activity. As a consequence, the fungi are exposed to the drug for a prolonged period of time leading to induction of resistance or the emergence of pre-existing azole resistant strains.
This study confirms the increasing importance of non C. albicans strains in patients with AIDS, but does not support the hypothesis that this could be the consequence of prolonged azole therapy, since the rate of azole resistance in non C. albicans strains was not statistically different in the cases and controls. In addition, our findings indicate that, despite all the above factors, extensive use of azole drugs is an independent risk factor for the emergence and the increasing prevalence of azole resistant Candida spp.
The role of previous use of azole drugs in selecting fluconazole resistant strains of Candida has been reported previously (Baily et al., 1994; Johnson et al., 1995; Rex et al., 1995) but this study indicates for the first time an analogous effect for itraconazole, possibly as a consequence both of cross reactivity between fluconazole and itraconazole and of the recent extensive use of itraconazole in the treatment of fungal infections in patients with HIV disease.
In conclusion, in view of the potential risk for the emergence and selection of azole resistant strains of Candida in patients with AIDS, it is important to carefully select an antifungal drug for the therapy of mild fungal infections after evaluation of the in-vitro sensitivity of the isolated strains. The increasing emergence of azole resistant strains of Candida spp. could be a limiting factor, not only for the therapy of oral candidosis, but, potentially, also for long term secondary prophylaxis in cryptococcal meningitis.
